580
Background:
Germline testing (GLT) identifies hereditary cancer syndromes and informs precision oncology care. NCCN guidelines recommend genetic evaluation for all patients with pancreatic cancer (Panc), those with high-risk or metastatic prostate cancer (PCa), and select patients with colorectal cancer (CR...
Yusra B. Medik, Evgeniya Pasternak, Trilok Shrivastava et al.· JCO Oncology Practice· 0 citations
Non-clear cell renal cell carcinomas comprise a heterogeneous group of kidney cancers with distinct biological features and clinical outcomes, and progress will depend on molecular stratification, subtype-specific trials, and integration of genomic and epigenomic insights to individualize prognosis and therapy.
Trilok Shrivastava, Yusra B. Medik, Nikhila Sampath Kumar et al.· Cancers· 0 citations
Immunotherapy has changed the landscape of bladder cancer treatment in recent years, both for localized and metastatic bladder cancer. While bacillus Calmette–Guérin (BCG) remains the gold standard for high-risk non–muscle-invasive bladder cancer, the development of checkpoint inhibitors continues to increase treatment...
N. Thalambedu, Krishna Vasipalli, N. Sampath Kumar et al.· Frontiers in Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
